On December 2nd (11 AM to 12 PM), the use of single-arm trials for Health Technology Appraisal (HTA) will be discussed in a panel presentation led by Dr. Bart Heeg, Vice President of Health Economics at Cytel. HTA bodies have begun accepting evidence from single-arm trials, but the heterogeneity of control data adds uncertainty to decision-making. Heeg and other participants Huseyin Naci, Joseph Cappelleri, and Dalia Dawoud will discuss whether network meta-analyses (NMAs) are appropriate for single-arm trial control selection.
According to a report by Mansha Sachdev, “Dr. Bart Heeg will argue that the bottle neck for the acceptability of single-arm trials for HTAs are not the limitations of NMAs, but in the selection of the historical/synthetic control arm, which are external control data used to evaluate the comparative effectiveness of an intervention.”
Find out more and download a session schedule by clicking here.
(Source: Cytel, November 23rd, 2021)
